v" A total of 216 patients with a ruptured aneurysm of the anterior part of the circle of Willis were enrolled into this prospective randomized study of timing of the operation after aneurysmal subarachnoid hemorrhage (SAH). Only patients in clinical Grades I to III (according to the classification of Hunt and Hess) who were admitted and randomly assigned to a treatment group within 72 hours after the SAH were included in the trial. The patients were randomly assigned to one of three operation groups: acute surgery (AS: 0 to 3 days after the SAH; day of SAH = Day 0), intermediate surgery (IS: 4 to 7 days after the SAH), or late surgery (LS: 8 days to an indefinite time after the SAH). Three patients (4.3%) in the IS group and six patients (8.6%) in the LS group died before surgery was undertaken. At 3 months post-SAH, 65 patients (91.5%) from the AS group were classified as independent compared to 55 (78.6%) from the IS group and 56 (80.0%) from the LS group. The management mortality rate in the AS group was 5.6% compared to 12.9% in the LS group.
T HE optimum timing of surgical intervention for ruptured intracranial aneurysms still remains controversial. In 1965, Norlrn ~9 reported operating on aneurysms during the 1 st or 2nd day after the subarachnoid hemorrhage (SAH). In 1975, he presented a series of 45 patients subjected to surgery within a week after the SAH; this series had a 4% operative mortality rate and 70% of the survivors returned to full working capacity (unpublished data). Many recent studies L4-6"8"1~-~7"2~ have shown that early aneurysm surgery in good-risk patients is not associated with higher mortality or morbidity rates, as suggested by proponents of late s u r g e r y . 2"9 There is, however, no prospective randomized study on the optimum timing of aneurysm surgery. The purpose of this investigation was to identify the optimum time for surgery in patients with ruptured aneurysms in the anterior circulation who are in good condition (Hunt and Hess 7 Grades I to III).
Clinical Material and M e t h o d s
Patients aged 16 to 65 years with a ruptured aneurysm located in the anterior part of the circle of Willis and admitted in clinical Grades I to III within 72 hours from their last SAH were enrolled in the study. Patients with an associated intracerebral hematoma and a decreased level of consciousness or severe neurological deficit were excluded. Other exclusion criteria were: pregnancy; hepatic or renal insufficiency; severe cardiac decompensation; and cardiac arrhythmia. No antifibrinolytic agents, hypertensive therapy, or volume expansion techniques were used. Betamethasone, 4 mg four times daily, was administered routinely in intramuscular injections. O f the 216 patients entered into the timing study, 159 were randomly assigned in an independent double-blind placebo-controlled study of the efficacy of nimodipine in preventing delayed ischemic deterioration after aneurysmal SAH and operation ("ni- modipine trial"). This study started later, after 52 patients had already been entered into the timing study. The patients in the nimodipine study received intravenous injections of either nimodipine (0.5 ug/kg/min) or equal amounts of placebo for 7 to 10 days after the SAH and, if the patient was operated on late, 2 to 3 days after the operation as well. After intravenous treatment, oral administration of nimodipine or placebo (60 mg six times daily) was continued up to 21 days after the SAH.
Operation Groups
After the diagnosis of an aneurysm, each patient was randomly assigned to one of the three operation groups by the drawing of an envelope where the time for operation was stated. There were 72 envelopes (patients) in each operation group, and a balanced randomization in blocks of 12 was used. The operation groups were as follows: acute surgery (AS: operation 0 to 3 days after the SAH; day of SAH = Day 0); intermediate surgery (IS: operation 4 to 7 days after the SAH); and late surgery (LS: operation 8 days to an indefinite time after the SAH). If the patient's clinical condition deteriorated because of delayed cerebral ischemia (DID) or rebleeding, he stayed in his own group even though the operation had to be postponed or performed immediately (as in the case of rebleeding with an associated large lifethreatening hematoma).
Within each operation group there was a randomization code list for 36 nimodipine and 36 placebo treatments. Of the 216 patients entered into the timing study, 79 received nimodipine (referred as the "nimodipine group") and 80 received placebo; 52 patients were not entered into the nimodipine trial. This left a total of 132 patients without nimodipine treatment (referred to as the "no-nimodipine group").
Radiological Investigations
All patients had a computerized tomography scan performed after admission. This was repeated in patients showing any clinical deterioration and, routinely, at hospital discharge. Bilateral carotid angiography and, if indicated, vertebral angiography were performed. Postoperative carotid angiography was performed in all cases immediately after the surgery under the same anesthesia or on the next day after the operation. These postoperative angiograms were evaluated for obliteration of the aneurysm, for severity and distribution of cerebral arterial spasm, and for the possible inclusion of a major arterial branch in the clip.
Assessment of Outcome
Neurological deficit or deterioration of the clinical state was attributed to one of the following causes: direct effect of the initial bleed, complication of the surgery, confirmed rebleeding, delayed ischemic deterioration ("vasospasm"), hydrocephalus, and extracranial complications. The outcome at 3 months post-SAH was assessed by using a three-point outcome scale. 22 The outcomes were categorized as independent (full neurological recovery or minimal to moderate disability), dependent (severe disability or vegetative state), or dead. Any deterioration in the patient's clinical condition was recorded in detail. 
Statistical Analysis
The operation groups were checked for comparability of demographic and clinical variables at entry by a t-test, and Fisher's exact and chi-square tests for categorical variables. In the final analysis of outcome at 3 months after the SAH, a comparison between the groups was made by the Mann-Whitney U-test and the significance of observed differences in outcome was assessed by Fisher's exact test. A p value of 0.05 or less was considered significant.
Exclusions after Randomization
Of the 216 patients entered into this study, five were found to be ineligible. The reasons for their ineligibility were as follows: in two patients the SAH was caused by rupture of a basilar aneurysm; two patients were in Grade IV upon admission; and one patient had an aneurysm but no SAH. No additional patients were excluded. No patients taking part in the nimodipine trial had their medication stopped before Day 21 unless they died.
Comparability of Operation Groups
A total of 71 patients were randomly assigned to the AS group, 70 to the IS group, and 70 to the LS group. The three operation groups were well matched for prognostic factors (Table l) . There were no significant differences among the operative groups in baseline values for radiographic variables (Table 2) . Randomization into the nimodipine trial was well balanced within the operation groups (Table 3) , and these patients did not show any significant differences between the treatment groups. In the AS group patients randomized into the nimodipine trial received intravenous medication (nimodipine or placebo) for a mean (+ standard deviation) of 6.9 _+ 1.9 days, in the IS group for a mean of 7.6 _+ 2.~ days, and in the LS group of a mean of 12.1 _+ 2.8 days.
Results

Surgical Intervention and Preoperative Deterioration
Surgery was performed on 71 patients (100%) in the AS group, on 67 patients (96%) in the IS group, and on 64 patients (91%) in the LS group. Altogether, 16 t Vasospasm = deficit due to delayed cerebral ischemia. Other = IS group: hypotension (one case), sepsis (one case).
patients were not operated on at the time stated because of severe deterioration or death before surgery. Three patients (4%) from the IS group and six patients (9%) from the LS group died before surgery, and seven operations had to be postponed (two patients in the AS group and five in the IS group). The neurological grade deteriorated preoperatively significantly more often in the LS group than in the AS group because of rebleeding (AS vs. LS p = 0.01) or delayed ischemia (AS vs. LS p = 0.0001; IS vs. LS p = 0.006). When the nimodipine and no-nimodipine groups were assessed separately for delayed ischemia, there was no significant difference between the operation groups in the nimodipine group whereas there was a significant difference between the groups in the no-nimodipine group (AS vs. LS p = 0.0004; IS vs. LS p = 0.02). The causes of deterioration in each group are shown in Tables 4 to 6 .
Overall Management Outcome
An evaluation 3 months post-SAH revealed no significant differences in the overall mortality between the operation groups. The mortality rate in the AS group was 6%, in the IS group 6%, and in the LS group 13%. In the AS group 65 patients (92%) were classified as independent, compared to 55 patients (79%) in the IS group and 56 (80%) in the LS group. A total of 11 patients (16%) in the IS group were classified as dependent, compared to two patients (3%) in the AS group. This difference was significant (p < 0.01). There were no other significant differences in the outcomes between the groups. The outcomes of the operation groups as a whole and in the no-nimodipine and nimodipine groups are shown in Table 7 .
Causes of Permanent Deficits
The occurrence and cause of permanent deficits are shown in Table 8 . There are no significant differences among the operation groups in the occurrence and cause of permanent deficits in the total patient material. Delayed cerebral ischemia caused a permanent deficit in 10 patients (16%) in the nimodipine group and in 37 patients (35%) in the no-nimodipine group. This difference was significant (p ---0.01, Fisher's two-tailed exact test). When the operation groups are analyzed separately, a significant difference is seen in the occurrence of permanent ischemic deficits between the LS groups (LS nimodipine vs. LS no-nimodipine, p = O.03).
Causes of Death
A total of three patients from the IS group and six from the LS group died before surgery was undertaken. Rebleeding was the cause of death in six cases (two in the IS group and four in the LS group) and DID in three (one in the IS group and two in the LS group). The occurrence and cause of all deaths are shown in Table 9 . Delayed cerebral ischemia caused death in one of the nimodipine-treated patients (LS group; 6% of all deaths) and in nine of the no-nimodipine patients (four in the AS group, two in the IS group, and three in the LS group; 53% of all deaths), but this difference was not significant. There were four deaths caused by rebleeding in the nimodipine group (one in the IS group and three in the LS group) and two in the no-nimodipine group (one in the IS group and one in the LS group). The operative mortality rate due to all causes was 5.6% (four patients) in the AS group, 1.5% in the IS group (one patient), and 4.7% in the LS group (three patients). There was only one postoperative death (4.0%) in the nimodipine LS group, caused by DID; all of the other postoperative deaths were in the no-nimodipine group. One death in the no-nimodipine LS group was caused by surgery; all the other deaths in the nonimodipine group were caused by DID.
Discussion
Several large series of patients submitted to early surgery after aneurysmal SAH have been published to date, 1,5,6"13-18 "2~ with the main purpose of stressing the technical feasibility and results of early surgery in the management of ruptured aneurysms. Management results with early surgery have been reported to be better than the management results with delayed surgery, 13-~8 although there are surgeons who still favor delayed operations. 2'9''~ When the calcium-antagonist nimodipine is combined with early surgery, the results are even better. 3'~6 One major problem in comparing the results published by various authors is the definition of the terms "acute" or "early" and "late" surgery. By "early" or "acute," many authors mean a period of 72 hours after the SAH, while others refer to an interval of 7 days from the SAH. One of the dilemmas for surgeons operating early is the timing of surgery in patients admitted on Days 4 to 7 after the SAH, because some reports indicate a higher surgical risk on Days 4 to 7 than on Days 0 to 3. 6'1~
There is no previous study where patients with aneurysmal SAH have been operated on within randomly selected time intervals after the SAH. The published nonrandomized series offer no proof for or against early or late surgery. The aim of the present study was to find the optimum timing for aneurysm surgery and to study the risk factors determining the patient's outcome. Randomization of the patients into the three operation groups was done within 72 hours after the SAH, thus avoiding a selection bias. The randomization was well balanced for all of the key prognostic factors that could affect the patient's outcome (Tables 1 to 3) .
Delayed cerebral ischemia was the main cause of preoperative deterioration in the LS group. There were 15 patients (21%) in the LS group whose neurological condition deteriorated preoperatively compared to one patient (1%) in the AS group (p = 0.0001) and to four patients (6%) in the IS group (p = 0.006). This difference was seen in the nimodipine-treated patients as well, but it did not reach the level of statistical significance as it did in the group of patients not treated with nimodipine.
Rebleeding was the cause of preoperative deterioration in two cases (3%) in the AS group, in six cases (9%) in the IS group, and in eight cases (11%) in the LS group. The difference between the AS and LS groups was significant (p = 0.01). When the nimodipine and no-nimodipine groups are compared separately, there is no statistical difference in the occurrence of rebleeds between the operation groups (Tables 4 to 6 ).
There were no differences between the operation groups in the occurrence and cause of permanent deficits. Delayed cerebral ischemia caused the vast majority of permanent deficits: 25% in the AS group, 17% in the IS group, and 24% in the LS group. When the nimodipine group is assessed separately, there is a significant difference in the number of deficits caused by 
* Numbers in parentheses are percentages. AS = acute surgery; IS = intermediate surgery; LS = late surgery. Vasospasm = deficit due to delayed cerebral ischemia. There were no significant differences between the operation groups.
delayed ischemia compared to the no-nimodipine group (10 cases in the nimodipine group vs. 37 cases in the no-nimodipine group, p = 0.01). The only significant difference in the occurrence of permanent deficit caused by delayed ischemia between the operation groups was in the LS group (two patients (7%) in the nimodipine group vs. 15 (36%) in the no-nimodipine group, p --0.03).
There was no significant difference in mortality rates between the operation groups --a result that was expected at the time the trial started, based on previous reports. 8'~7"23 The number of disabled patients was high in the IS group, and the outcomes in the AS and IS groups differed significantly because of the greater number of dependent patients in the IS group. These results are similar to those previously reported. 6 In the overall outcome at 3 months after the SAH, the only significant difference between the operation groups was in the number of dependent patients in the AS and IS groups. Two patients (3%) from the AS group and 11 patients (16%) from the IS group were classified as dependent. This difference was seen in the no-nimodipine group as well (one dependent (12 %) in the IS group). There were a total of nine deaths in the LS group compared to four deaths in the AS and IS groups; the difference between the groups was not significant. Delayed cerebral ischemia caused death in nine no-nimodipine patients and in only one nimodipinetreated patient; this difference, however, was not significant.
Nimodipine treatment complicated the interpretation of the results. When the nimodipine-treated patient group is analyzed separately and is compared to the nonimodipine group, the results differ significantly. Nimodipine treatment was associated with a significantly lower incidence of preoperative deterioration caused by DID (p = 0.03), and the occurrence of permanent deficits caused by DID was aJso significantly lower in the nimodipine group (p = 0.01).
Operation within 3 days after the SAH was not associated with higher mortality or morbidity rates; there were no deaths caused by rebleeding in this group or in the nimodipine-treated or non-treated groups. In the outcome at 3 months after the SAH there was a trend toward better results in the AS group, but this difference was not significant. Our conclusion is that operation at the acute stage yields better results than does delayed surgery. Other advantages of acute-stage operation are the reduction of the length and cost of inpatient treatment. Acute operation within 72 hours after the hemorrhage combined with intravenous nimodipine treatment yields even better results, preventing fatal rebleeds and significantly lowering, although not reversing, the incidence and severity of delayed ischemic deficits.
